Genetic basis for primary ovarian insuiciency

Luca Persani, Stephanie Sherman, Lawrence Nelson

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction Approximately 1% of women under the age of 40 years and 0.1% under the age of 30 years experience “premature menopause” [1]. “Premature menopause” or “premature ovarian failure” (POF) has generally been defined as 4–6 months of amenorrhea in women under the age of 40 years associated with serum gonadotropin concentrations in the postmenopausal range and hypoestrogenism (hypergonadotropic hypogonadism). Depending on the age of onset, the disorder can manifest as failure to enter pubertal development and the associated primary amenorrhea (PA), or secondary amenorrhea (SA) after the onset of menarche and the associated pubertal development [2, 3]. Substantial published evidence has demonstrated that POF may have a long and variable clinical course with the possibility of spontaneous remission and even pregnancy many years after the diagnosis. Therefore, the term primary ovarian insufficiency (POI) is now generally accepted as a less stigmatizing term to young women. It is, as well, a more scientifically accurate definition, to describe more clearly a continuum of intermittent and unpredictable ovarian function [4, 5]. The continuum is divided into two categories of clinical states: (1) POI that is overt, meaning that menstrual cycles have become irregular, and (2) POI that is occult (oPOI), meaning that the menstrual cycles are still regular but other evidence supports a conclusion that ovarian function is impaired [5]. POI generates two orders of consequences, hypoestrogenism and infertility at an early age. Hypoestrogenism can nowadays be acceptably treated by hormone replacement therapy, generally given until the age of physiological menopause. In contrast, fertility cannot be recovered when follicle-stimulating hormone (FSH) is in the menopausal range and the diagnosis of overt POI is made. Also, fertility may well be compromised in the phase of the disease when the clinical manifestations are absent (oPOI). The relevance of this disorder is growing dramatically in recent years because women tend to postpone their conception due to economic reasons or working opportunities.

Original languageEnglish
Title of host publicationBiology and Pathology of the Oocyte: Role in Fertility, Medicine, and Nuclear Reprogramming, Second Edition
PublisherCambridge University Press
Pages394-408
Number of pages15
ISBN (Print)9781139135030, 9781107021907
DOIs
Publication statusPublished - Jan 1 2012

Fingerprint

Primary Ovarian Insufficiency
Amenorrhea
Premature Menopause
Menstrual Cycle
Fertility
Spontaneous Remission
Menarche
Hypogonadism
Hormone Replacement Therapy
Follicle Stimulating Hormone
Menopause
Gonadotropins
Age of Onset
Infertility
Economics
Pregnancy
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Persani, L., Sherman, S., & Nelson, L. (2012). Genetic basis for primary ovarian insuiciency. In Biology and Pathology of the Oocyte: Role in Fertility, Medicine, and Nuclear Reprogramming, Second Edition (pp. 394-408). Cambridge University Press. https://doi.org/10.1017/CBO9781139135030.035

Genetic basis for primary ovarian insuiciency. / Persani, Luca; Sherman, Stephanie; Nelson, Lawrence.

Biology and Pathology of the Oocyte: Role in Fertility, Medicine, and Nuclear Reprogramming, Second Edition. Cambridge University Press, 2012. p. 394-408.

Research output: Chapter in Book/Report/Conference proceedingChapter

Persani, L, Sherman, S & Nelson, L 2012, Genetic basis for primary ovarian insuiciency. in Biology and Pathology of the Oocyte: Role in Fertility, Medicine, and Nuclear Reprogramming, Second Edition. Cambridge University Press, pp. 394-408. https://doi.org/10.1017/CBO9781139135030.035
Persani L, Sherman S, Nelson L. Genetic basis for primary ovarian insuiciency. In Biology and Pathology of the Oocyte: Role in Fertility, Medicine, and Nuclear Reprogramming, Second Edition. Cambridge University Press. 2012. p. 394-408 https://doi.org/10.1017/CBO9781139135030.035
Persani, Luca ; Sherman, Stephanie ; Nelson, Lawrence. / Genetic basis for primary ovarian insuiciency. Biology and Pathology of the Oocyte: Role in Fertility, Medicine, and Nuclear Reprogramming, Second Edition. Cambridge University Press, 2012. pp. 394-408
@inbook{649ca26f1d8b4e209c265368c7efdf25,
title = "Genetic basis for primary ovarian insuiciency",
abstract = "Introduction Approximately 1{\%} of women under the age of 40 years and 0.1{\%} under the age of 30 years experience “premature menopause” [1]. “Premature menopause” or “premature ovarian failure” (POF) has generally been defined as 4–6 months of amenorrhea in women under the age of 40 years associated with serum gonadotropin concentrations in the postmenopausal range and hypoestrogenism (hypergonadotropic hypogonadism). Depending on the age of onset, the disorder can manifest as failure to enter pubertal development and the associated primary amenorrhea (PA), or secondary amenorrhea (SA) after the onset of menarche and the associated pubertal development [2, 3]. Substantial published evidence has demonstrated that POF may have a long and variable clinical course with the possibility of spontaneous remission and even pregnancy many years after the diagnosis. Therefore, the term primary ovarian insufficiency (POI) is now generally accepted as a less stigmatizing term to young women. It is, as well, a more scientifically accurate definition, to describe more clearly a continuum of intermittent and unpredictable ovarian function [4, 5]. The continuum is divided into two categories of clinical states: (1) POI that is overt, meaning that menstrual cycles have become irregular, and (2) POI that is occult (oPOI), meaning that the menstrual cycles are still regular but other evidence supports a conclusion that ovarian function is impaired [5]. POI generates two orders of consequences, hypoestrogenism and infertility at an early age. Hypoestrogenism can nowadays be acceptably treated by hormone replacement therapy, generally given until the age of physiological menopause. In contrast, fertility cannot be recovered when follicle-stimulating hormone (FSH) is in the menopausal range and the diagnosis of overt POI is made. Also, fertility may well be compromised in the phase of the disease when the clinical manifestations are absent (oPOI). The relevance of this disorder is growing dramatically in recent years because women tend to postpone their conception due to economic reasons or working opportunities.",
author = "Luca Persani and Stephanie Sherman and Lawrence Nelson",
year = "2012",
month = "1",
day = "1",
doi = "10.1017/CBO9781139135030.035",
language = "English",
isbn = "9781139135030",
pages = "394--408",
booktitle = "Biology and Pathology of the Oocyte: Role in Fertility, Medicine, and Nuclear Reprogramming, Second Edition",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Genetic basis for primary ovarian insuiciency

AU - Persani, Luca

AU - Sherman, Stephanie

AU - Nelson, Lawrence

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Introduction Approximately 1% of women under the age of 40 years and 0.1% under the age of 30 years experience “premature menopause” [1]. “Premature menopause” or “premature ovarian failure” (POF) has generally been defined as 4–6 months of amenorrhea in women under the age of 40 years associated with serum gonadotropin concentrations in the postmenopausal range and hypoestrogenism (hypergonadotropic hypogonadism). Depending on the age of onset, the disorder can manifest as failure to enter pubertal development and the associated primary amenorrhea (PA), or secondary amenorrhea (SA) after the onset of menarche and the associated pubertal development [2, 3]. Substantial published evidence has demonstrated that POF may have a long and variable clinical course with the possibility of spontaneous remission and even pregnancy many years after the diagnosis. Therefore, the term primary ovarian insufficiency (POI) is now generally accepted as a less stigmatizing term to young women. It is, as well, a more scientifically accurate definition, to describe more clearly a continuum of intermittent and unpredictable ovarian function [4, 5]. The continuum is divided into two categories of clinical states: (1) POI that is overt, meaning that menstrual cycles have become irregular, and (2) POI that is occult (oPOI), meaning that the menstrual cycles are still regular but other evidence supports a conclusion that ovarian function is impaired [5]. POI generates two orders of consequences, hypoestrogenism and infertility at an early age. Hypoestrogenism can nowadays be acceptably treated by hormone replacement therapy, generally given until the age of physiological menopause. In contrast, fertility cannot be recovered when follicle-stimulating hormone (FSH) is in the menopausal range and the diagnosis of overt POI is made. Also, fertility may well be compromised in the phase of the disease when the clinical manifestations are absent (oPOI). The relevance of this disorder is growing dramatically in recent years because women tend to postpone their conception due to economic reasons or working opportunities.

AB - Introduction Approximately 1% of women under the age of 40 years and 0.1% under the age of 30 years experience “premature menopause” [1]. “Premature menopause” or “premature ovarian failure” (POF) has generally been defined as 4–6 months of amenorrhea in women under the age of 40 years associated with serum gonadotropin concentrations in the postmenopausal range and hypoestrogenism (hypergonadotropic hypogonadism). Depending on the age of onset, the disorder can manifest as failure to enter pubertal development and the associated primary amenorrhea (PA), or secondary amenorrhea (SA) after the onset of menarche and the associated pubertal development [2, 3]. Substantial published evidence has demonstrated that POF may have a long and variable clinical course with the possibility of spontaneous remission and even pregnancy many years after the diagnosis. Therefore, the term primary ovarian insufficiency (POI) is now generally accepted as a less stigmatizing term to young women. It is, as well, a more scientifically accurate definition, to describe more clearly a continuum of intermittent and unpredictable ovarian function [4, 5]. The continuum is divided into two categories of clinical states: (1) POI that is overt, meaning that menstrual cycles have become irregular, and (2) POI that is occult (oPOI), meaning that the menstrual cycles are still regular but other evidence supports a conclusion that ovarian function is impaired [5]. POI generates two orders of consequences, hypoestrogenism and infertility at an early age. Hypoestrogenism can nowadays be acceptably treated by hormone replacement therapy, generally given until the age of physiological menopause. In contrast, fertility cannot be recovered when follicle-stimulating hormone (FSH) is in the menopausal range and the diagnosis of overt POI is made. Also, fertility may well be compromised in the phase of the disease when the clinical manifestations are absent (oPOI). The relevance of this disorder is growing dramatically in recent years because women tend to postpone their conception due to economic reasons or working opportunities.

UR - http://www.scopus.com/inward/record.url?scp=84928071555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928071555&partnerID=8YFLogxK

U2 - 10.1017/CBO9781139135030.035

DO - 10.1017/CBO9781139135030.035

M3 - Chapter

AN - SCOPUS:84928071555

SN - 9781139135030

SN - 9781107021907

SP - 394

EP - 408

BT - Biology and Pathology of the Oocyte: Role in Fertility, Medicine, and Nuclear Reprogramming, Second Edition

PB - Cambridge University Press

ER -